Page last updated: 2024-08-26

yttrium radioisotopes and Leukemia, Pre-B-Cell

yttrium radioisotopes has been researched along with Leukemia, Pre-B-Cell in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bodet-Milin, C; Chevallier, P; Delaunay, J; Escoffre-Barbe, M; Eugene, T; Goldenberg, DM; Guillaume, T; Kraeber-Bodéré, F; Le Houerou, C; Menard, A; Robillard, N; Wegener, WA	1
Barbet, J; Bene, MC; Bodet-Milin, C; Cherel, M; Chevallier, P; Delaunay, J; Escoffre-Barbe, M; Eugene, T; Eveillard, M; Faivre-Chauvet, A; Ferrer, L; Gaschet, J; Goldenberg, DM; Guillaume, T; Huguet, F; Hunault, M; Ifrah, N; Isnard, F; Kraeber-Bodéré, F; Lapusan, S; Le Houerou, C; Marcais, A; Nicolini, F; Peterlin, P; Robillard, N; Thomas, X; Wegener, WA	1

Trials

1 trial(s) available for yttrium radioisotopes and Leukemia, Pre-B-Cell

Article	Year
(90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. The Lancet. Haematology, 2015, Volume: 2, Issue:3 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Female; France; Humans; Male; Maximum Tolerated Dose; Middle Aged; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Radioimmunotherapy; Sialic Acid Binding Ig-like Lectin 2; Treatment Outcome; Yttrium Radioisotopes	2015

Article

Year

(90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.

The Lancet. Haematology, 2015, Volume: 2, Issue:3

Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Female; France; Humans; Male; Maximum Tolerated Dose; Middle Aged; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Radioimmunotherapy; Sialic Acid Binding Ig-like Lectin 2; Treatment Outcome; Yttrium Radioisotopes

2015

Other Studies

1 other study(ies) available for yttrium radioisotopes and Leukemia, Pre-B-Cell

Article	Year
BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle. European journal of haematology, 2013, Volume: 91, Issue:6 Topics: Antibodies, Monoclonal, Humanized; Bone Marrow; Female; Fusion Proteins, bcr-abl; Humans; Immunophenotyping; Middle Aged; Neoplasm, Residual; Phenotype; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Radioimmunotherapy; Remission Induction; Sialic Acid Binding Ig-like Lectin 2; Treatment Outcome; Yttrium Radioisotopes	2013

Article

Year

BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle.

European journal of haematology, 2013, Volume: 91, Issue:6

Topics: Antibodies, Monoclonal, Humanized; Bone Marrow; Female; Fusion Proteins, bcr-abl; Humans; Immunophenotyping; Middle Aged; Neoplasm, Residual; Phenotype; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Radioimmunotherapy; Remission Induction; Sialic Acid Binding Ig-like Lectin 2; Treatment Outcome; Yttrium Radioisotopes

2013